Essential Biomarkers & Genetic Alterations Evaluated
Precision oncology requires rigorous verification of somatic mutations, protein expression, and genomic signatures before finalizing a treatment protocol.
RNA Sequencing & Gene Fusion Panels
Detects pathognomonic fusions (NTRK1/2/3, EWSR1, SS18-SSX, RET, FGFR2/3) that define exact sarcoma and carcinoma subtypes.
Ki-67 Proliferation Index & Mitotic Rate
Essential for grading neuroendocrine tumors (NETs Grade 1/2 vs Neuroendocrine Carcinoma G3) which dictates completely different treatments.
KIT & PDGFRA Mutation Mapping
Identifies primary and secondary resistance mutations in GIST to optimize imatinib, sunitinib, regorafenib, or ripretinib dosing.
Somatostatin Receptor (SSTR) Imaging Avidity
Confirms suitability for Peptide Receptor Radionuclide Therapy (PRRT / Lutathera) in metastatic well-differentiated NETs.
Comprehensive MSI, TMB & dMMR Status
Allows tumor-agnostic immunotherapy access (Pembrolizumab, Dostarlimab) regardless of the anatomical site of origin.
Critical Treatment Decisions Addressed in Your Review
Our multidisciplinary panel examines your case from medical oncology, surgical, and radiation oncology angles to address these pivotal questions:
Central Histopathology Re-Classification
Correcting misdiagnosed benign vs malignant lesions or misidentified sarcoma histologic subtypes (over 70 distinct entities).
Limb-Sparing Surgery vs Amputation
Multidisciplinary review of pre-operative radiation and hyperthermic isolated limb perfusion to preserve extremity function.
PRRT vs Targeted Therapy for NETs
Sequencing Lutetium-177 Dotatate, Everolimus, Sunitinib, and hepatic embolization for advanced neuroendocrine disease.
NCI Rare Tumor Clinical Trial Access
Screening patients for NCI-MATCH, TAPUR, and early-phase basket trials with novel molecular compounds.
Records Required for Rare Cancers Second Opinion
Upload your files online. Our team coordinates directly with your hospital if records are incomplete.
Pathology & Biopsy Reports
Complete histopathology, tumor margin documentation, and formal IHC score sheets.
Raw DICOM Scans
CT, MRI, PET-CT discs or digital cloud download links (not just radiologist text summaries).
Genomic & NGS Panels
FoundationOne, Guardant, Tempus, or specialized assay reports (e.g. Oncotype, Decipher).
Frequently Asked Questions: Rare Cancers
Clear clinical answers regarding diagnostic accuracy, surgical options, and biomarker interpretation.
Related Second Opinion & Diagnostic Services
Cancer decisions intersect pathology, radiology, and adjacent disease subspecialties.
Cancer Pathology Second Opinion
Pathology is the foundational blueprint of every cancer diagnosis, yet it is inherently interpretive. Major peer-reviewed medical studies document that 15% to 30% of second-look pathology reviews uncover diagnostic discordance: benign conditions mistaken for malignant tumors, incorrect tumor staging, missed lymphovascular invasion, or discordant hormone receptor/HER2 status that profoundly alters systemic treatment.
Cancer Radiology Second Opinion
Radiology reports are often produced under high-volume general hospital conditions where subtle oncologic nuances can be overlooked. Up to 20% of expert radiology second opinions identify critical discrepancies: unrecognized liver or peritoneal metastases, missed vascular encasement that alters surgical resectability, or confusion between treatment-induced pseudo-progression and true tumor growth.
Breast Cancer Second Opinion
Breast cancer care has evolved from one-size-fits-all chemotherapy to biomarker-driven, subtype-specific regimens. Second opinions frequently alter therapy by re-evaluating borderline HER2-low vs HER2-zero immunohistochemistry (IHC 1+ or IHC 2+/FISH negative), verifying ER/PR expression cutoffs, interpreting ambiguous Oncotype DX or MammaPrint genomic recurrence scores, and assessing surgical lumpectomy margins.
Complete Second Opinion Guide
Compare multidisciplinary reviews, read about record transfer logistics, and review transparent $450 flat pricing.
Get an Independent Second Opinion on Your Rare Cancers Diagnosis
Upload your biopsy pathology slides, NGS reports, and DICOM scans. Receive a comprehensive multidisciplinary written report and staging audit within 12 to 72 hours.